Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells

Blood

Volumn 102, Issue 4, 2003, Pages 1490-1498

  Selleri, Carmine ^a   Maciejewski, Jaroslaw P ^b   Montuori, Nunzia ^b   Ricci, Patrizia ^b   Visconte, Valeria ^b   Serio, Bianca ^b   Luciano, Luigiana ^b   Rotoli, Bruno ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD34 ANTIGEN; FAS LIGAND; FAS RECEPTOR; LONAFARNIB; MESSENGER RNA; NITRIC OXIDE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DISEASE PREDISPOSITION; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTRACELLULAR SPACE; LEUKEMIA CELL; MALE; OBSERVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0042237727     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0178     Document Type: Article

References (66)

1. Clark GJ, Der CJ. Ras proto-oncogene activation in human malignancy. In: Garrett CT, Sell S, eds. Cellular Cancer Markers. Totowa, NJ: Humana Press; 1995:17-52.
2. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol. 1999;17:3631-3652.
3. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim Biophys Acta. 1999;1423:19-30.
4. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst. 2001;93: 1062-1074.
5. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999;13:502-513.
6. Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr Opin Hematol. 1995;2:305-308.
7. Byrne JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: Ras revisited. Br J Haematol. 1998;100:256-264.
8. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood. 2000;96:1655-1669.
9. Parker J, Mufti GJ. Ras and myelodysplasia: lessons from the last decade. Semin Hematol. 1996; 33:206-224.
10. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene. 1998;17:1395-1413.
11. Reuther CW, Der CJ. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr Opin Cell Biol. 2000;12:157-165.
12. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. Science. 1997; 275:1750-1751.
13. Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem. 1996;271:5289-5292.
14. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-tobedside translational studies. Oncogene. 2000; 19:6584-6593.
15. Houssin R, Pommery J, Salaun MC, et al. Design, synthesis, and pharmacological evaluation of new farnesyl protein transferase inhibitors. J Med Chem. 2002;45:533-536.
16. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
17. Karp JE. Farnesyltransferase inhibitors as targeted therapies for hematological malignancies. Semin Hematol. 2001;38(suppl 7):16-23.
18. Cortes J, Kurzrock R, O'Brien SM. Phase I study of a farnesyl transferase inhibitor (FTI), BMS-214662, in patients with refractory or relapsed acute leukemias [abstract]. Blood. 2001: 98;594a.
19. Peters DG, Hoover RR, Gerlach MJ, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.
20. Morgan MA, Dolp O, Reuter CWM. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. Blood. 2001;97:1823-1834.
21. Kurzrock R. Myelodysplastic syndrome overview. Semin Hematol. 2002;39(suppl 2):18-25.
22. Lebowitz PF, Prendergast GC. Non-ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998;17:1439-1447.
23. Prendergast GC, Du W.Targeting farnesyltransferase: is Ras relevant? Drug Resist Updat. 1999; 2:81-84.
24. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 1999;19:1831-1840.
25. Prendergast GC. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol. 2000;12:166-173.
26. Du W, Prendergast GC. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. Cancer Res. 1999;59:5492-5496.
27. Adjei AA, Davis JN, Erlichman C, Svingen PA, Kaufmann SH. Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res. 2000;6:2318-2325.
28. Cox AD, Der CJ. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta. 1997;1333:51-71.
29. Zhang B, Prendergast GC, Fenton RG, Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res. 2002; 62:452-458.
30. Liu AX, Du W, Liu JP, Jessell TM, Prendergast GC. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol Cell Biol. 2000;20:6105-6113.
31. Liu AX, Cerniglia GJ, Bernhard EJ, Prendergast GC. RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc Natl Acad Sci U S A. 2001;98:6192-6197.
32. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med. 1995;181:307-313.
33. Faderl S,Talpaz M, Estrow Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
34. Zou X, Calame K. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J Biol Chem. 1999;274:18141-18144.
35. Skorski T, Wlodarski P, Daheron L, et al. BCR/ ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci U S A. 1998;95:11858-11862.
36. Majewski M, Nieborowska-Skorska M, Salomoni P, et al. Activation of mitochondrial Raf-1 is involved in the antiapoptotic effects of Akt. Cancer Res. 1999;59:2815-2819.
37. Dickens M, Rogers JS, Cavanagh J, et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 1997;277:693-697.
38. Shi CS,Tuscano JM, Witte ON, Kehrl JH. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway. Blood. 1999;93: 1338-1345.
39. Di Cristofano A, Niki M, Zhao M, et al. p62(dok),a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J Exp Med. 2001;194: 275-284.
40. Sonoyama J, Matsumura I, Ezoe S, et al. Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. J Biol Chem. 2002;277:8076-8082.
41. Hoover RR, Gerlach MJ, Koh EY, Daley GQ. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene. 2001;20:5826-5835.
42. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro: contribution to inhibitory action of interferongamma and tumor necrosis factor-alpha. J Clin Invest. 1995;96:1085-1092.
43. Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci U S A. 1998;95:15356-15361.
44. Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem. 2002;383:411-423.
45. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyltransferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003,101:1692-1697.
46. Keating A. Chronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors. Semin Hematol. 2002;39(suppl 2):11-17.
47. Cortes JE, Daley G, Talpaz M, et al. Pilot study of SCH66336 (Lonafarnib), a farnesyltransferase inhibitor (FTI), in patients with chronic myeloid leukemia (CML), in chronic or accelerated phase resistant or refractory to imatinib [abstract]. Blood. 2002;100:164a.
48. Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP, Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyl-transferase inhibitors. Blood. 2000;95:639-645.
49. Skorski T. BCR/ABL regulates response to DNA damage: the role inresistance to genotoxic treatment and in genomic instability. Oncogene. 2002; 21:8591-8604.
50. Selleri C, Maciejewski JP, Pane F, et al. Fas-mediated modulation o Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 1998;92:981-989.
51. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89:957-964.
52. Pane F, Mostarda I, Selleri C, et al. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients. Blood. 1999;94:2200-2207.
53. Tatsuta T, Shiraishi A, Mountz JD. The prodomain of caspase-1 enhances Fas-mediated apoptosis through facilitation of caspase-8 activation. J Biol Chem. 2000;275:14248-14254.
54. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
55. Arnoult D, Parone P, Martinou JC, Antonsson B, Estaquier J, Ameisen JC. Mitochondrial release of apoptosis-inducing factor occurs downstream of cytochrome c release in response to several proapoptotic stimuli. J Cell Biol. 2002;159:923-929.
56. Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91:1700-1705.
57. Tsujimoto Y. Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep. 2002; 22:47-58.
58. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A. 1995;92:5287-5291.
59. Frassanito MA, Cusmai A, Piccoli C, Dammacco F. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells. Br J Haematol. 2002; 118:157-165.
60. Kolb JP. Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. Leukemia. 2000;14:1685-1694.
61. - Ferry-Dumazet H, Mamani-Matsuda M, Dupouy M, et al. Nitric oxide induces the apoptosis of human BCR-ABL-positive myeloid leukemia cells: evidence for the chelation of intracellular iron. Leukemia. 2002;16:708-715.
62. Selleri C, Maciejewski JP. Nitric oxide and cell survival: megakaryocytes say "NO." J Lab Clin Med. 2001;137:225-230.
63. Pervin S, Singh R, Gau CL, Edamatsu H, Tamanoi F, Chaudhuri G. Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. Cancer Res. 2001;61:4701-4706.
64. Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci. 2001;58:1636-1649.
65. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem. 2000;275:17974-17978.
66. Hoover RR, Mahon FX, Melo JV, Daley GQ Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 2002; 100:1068-1071.